Change log
Updates: what changed, when and why
Every recorded change, with the previous value, the new value and the reason. A correction of our own error is marked differently from a later change at the source.
A correction of this site's own error is labelled as a correction. A change made by a provider or by a plan is labelled as a change. The two are never merged, because they mean different things to a reader deciding whether to trust an old figure.
Log
This table scrolls sideways.
| Date | Version | Type | Previous | New | Reason | Affected records | Editor | Reviewer | Next due |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-01 | dataset v1.3 | source recheck | Canada Life Wegovy and Zepbound forms 3/26 and 2/26; PSHCP Wegovy 4/26; Express Scripts Zepbound September 2026 file; 40 Manulife files at the earlier portal addresses | Monthly forms check: six Canada Life forms replaced with the 8/26 and 10/26 versions (Zepbound adds an obstructive sleep apnea section; PSHCP Wegovy adds a prior diet or exercise attempt question); Express Scripts Zepbound replaced (wording only); 40 Manulife forms replaced from their new portal addresses (same version codes; online claim steps reworded); Medavie Wegovy, Zepbound and Saxenda official link marked not working; Beneva fingerprints recorded | Insurers changed the forms at the source; found by the 1 November 2026 monthly check | insurance forms (/insurance-forms/) | build chat (owner approved) | not required (insurers’ own forms copied unchanged; criteria summaries read from the forms) | 2026-12-01 |
| 2026-10-11 | dataset v1.3 | source added | none | Obesity Canada links: appeal letter template on the insurance forms page, guideline chapters on the care options page, the October 2026 national report on the coverage page | Useful public resources for readers; no data values changed | claims R44-C01 to R44-C04 | research chat (owner reviewed) | not required (links and dated statements only) | 2026-11-10 |
| 2026-10-04 | dataset v1.3 | new evidence | 105 study explainers | 111 study explainers: TRIUMPH-1, TRIUMPH-2, ATTAIN-2, ACHIEVE-4 and two 2026 reviews | Published after the last library update; reviewed and signed 2026-10-04 | evidence library; claims R33-C01 to R33-C16 | research chat (owner reviewed) | two pharmacists registered in British Columbia (evidence pages) | 2026-11-03 |
| 2026-10-04 | dataset v1.3 | new page | no private plan record | Prior authorization forms page: 219 insurer forms in English and French, with how private coverage works | Readers and pharmacists search for insurer forms | /insurance-forms/; claims R43-C24 to R43-C36 | research chat (owner reviewed) | two pharmacists registered in British Columbia (evidence pages) | 2026-11-03 |
| 2026-10-04 | dataset v1.3 | new page | pipeline products listed on the semaglutide page only | Status pages for orforglipron (Foundayo) and retatrutide | Search demand; US approval of Foundayo on 2026-04-01; TRIUMPH results published 2026-09-29 | products.csv pipeline rows; claims R43-C01 to R43-C11 | research chat (owner reviewed) | two pharmacists registered in British Columbia (evidence pages) | 2026-11-03 |
| 2026-10-04 | dataset v1.3 | new page | generics listed on the semaglutide page | Generic semaglutide page with Sandoz approval (2026-09-16), Ontario prices and four recalls | New approval and recalls since the last check | claims R43-C12 to R43-C16 | research chat (owner reviewed) | two pharmacists registered in British Columbia (evidence pages) | 2026-11-03 |
| 2026-10-04 | dataset v1.3 | new page | none | Eligibility page: Health Canada criteria for Wegovy, Sevmia, Zepbound and Saxenda, and plan criteria | Search demand for eligibility questions | /medicines/wegovy-zepbound-eligibility-canada/ | research chat (owner reviewed) | two pharmacists registered in British Columbia (evidence pages) | 2026-11-03 |
| 2026-10-04 | dataset v1.3 | source recheck | province pages without plan questions | Common questions on BC, ON, NS, NB and QC pages: Special Authority, Trillium, OHIP+, exception status and Quebec private plans; CDA-AMC Zepbound recommendation; BC Zepbound review | Official criteria documents dated September 2026 | claims R43-C17 to R43-C25 | research chat (owner reviewed) | two pharmacists registered in British Columbia (evidence pages) | 2026-11-03 |
| 2026-09-27 | dataset v1.2 | recheck | Seven provider records last checked 2026-09-23 | All seven rechecked on 2026-09-27 against the providers' own pages; most values unchanged | Scheduled weekly recheck: R42-C01, R42-C08, R42-C12, R42-C17, R42-C20, R42-C24, R42-C28 | all provider records | build chat | owner review pending | 2026-10-04 |
| 2026-09-27 | dataset v1.2 | provider change observed | Felix Quebec: not named | Explicitly not offered: a Felix help article says it cannot provide care in Quebec | New provider statement: R42-C02 | svc-felix-weight QC | build chat | owner review pending | 2026-10-04 |
| 2026-09-27 | dataset v1.2 | provider change observed | Felix language: not found; billing and insurance without these terms | English-only care (terms); payment in full before weight care; $35 per insurance form; $10 reshipment fee | New provider statements: R42-C03 to R42-C06 | svc-felix-weight | build chat | owner review pending | 2026-10-04 |
| 2026-09-27 | dataset v1.2 | provider change observed | Jill delivery: not found; first month read as a waived initial fee | Free shipping; no shipping to NB, NT, PE, NU, YT (company-wide); first-month wording now conflicting across Jill pages | Provider pages differ: R42-C13 to R42-C16 | svc-jill-weight; conf-jill-first-month | build chat | owner review pending | 2026-10-04 |
| 2026-09-27 | dataset v1.2 | provider change observed | Phoenix follow-ups: $40 to $50 per visit | Still $40 to $50 on the pricing page; the treatment page advertises unlimited follow-ups. New open conflict. Wegovy price conflict updated | Provider pages differ: R42-C25 to R42-C27 | svc-phoenix-weight; conf-phoenix-follow-up-fee; conf-phoenix-wegovy-price | build chat | owner review pending | 2026-10-04 |
| 2026-09-27 | dataset v1.2 | provider change observed | Pocketpills dispensing: not found; Ozempic $139 unit not stated | Dispensing fee charged, amount not stated; product prices shown per month and footnoted per pen (Ozempic $139, Wegovy from $387, Mounjaro $329, Zepbound $329, Saxenda $247) | New provider statements: R42-C29 to R42-C31 | svc-pocketpills-weight | build chat | owner review pending | 2026-10-04 |
| 2026-09-27 | dataset v1.2 | provider change observed | Maple, MedWeight, Hims: values unchanged | Added: Maple non-refundable wording and sublingual pharmacy rule; MedWeight $40 no-show fee, English-only sessions and a required program manual; Hims partner pharmacies in ON and BC and no lock-in. Hims first-consult fee is a switchable promotion | New provider statements: R42-C09 to R42-C11, R42-C18 to R42-C23 | svc-maple-weight-assessment; svc-medweight-msp; svc-hims-weight; conf-hims-first-consult | build chat | owner review pending | 2026-10-04 |
| 2026-09-27 | dataset v1.2 | recheck | BC Wegovy: Non-benefit (decision 18 Dec 2025) | Unchanged: formulary search (coverage updated 15 Sep 2026) shows all Wegovy DINs Non-Benefit; the decisions page (updated 23 Sep 2026) still lists the Dec 2025 Non-benefit decision. A March 2026 news report that BC approved Wegovy for weight management is not supported by the primary sources | Recheck prompted by conflicting news coverage: R42-C32 | BC coverage record | build chat | owner review pending | 2026-10-16 |
| 2026-09-23 | site build 0.6 | addition | No editorial imagery; identity artwork only | Ten AI-generated editorial illustrations added, one per primary route (home, compare, costs, coverage, provinces, medicines, evidence, care options, about, ask). Eight carry original reading-note text or verified article citations (STEP 1 2021, SURMOUNT-1 2022, Canadian adult obesity guideline 2020). Each is captioned as AI-generated; the About page carries the shared provenance statement. | Owner-approved imagery release (11-website-imagery text-v2). No fact, claim, review state, route or tool changed. | ten primary routes; site/assets/images/ | build chat | owner | not applicable |
| 2026-09-23 | dataset v1.1 | recheck | Provider records last read 2026-09-17 | All seven provider records reread on their public pages on 2026-09-23 (R4-1, 101 source rows). Unchanged facts now carry both dates; conflicts that persist stay open with a dated history | Scheduled weekly recheck of fees, province lists and terms | all seven /providers/ pages; /compare/; /costs/; /provinces/ pages | build chat, from the R4-1 provider recheck | owner review pending | 2026-09-30 |
| 2026-09-23 | dataset v1.1 | correction | Jill Health initial care fee shown as '$0 introductory' | '$0 initial fee (waived), then $59 per month; not a free first month', with the three-month enrolment and renewal conditions shown separately | Correction of this site's own comparison wording against the provider page (R41-C78 to R41-C83); not evidence that Jill changed its offer | svc-jill-weight initial and recurring care; /compare/ | build chat | owner review pending | 2026-09-30 |
| 2026-09-23 | dataset v1.1 | correction | Felix weight service in Prince Edward Island shown as offered | Shown as conflicting: the weight help page lists PEI and the weight funnel page omits it | Both pages reread 2026-09-23 (R41-C01, R41-C02); the record had followed one page only | svc-felix-weight PE; /provinces/prince-edward-island/; /compare/ | build chat | owner review pending | 2026-09-30 |
| 2026-09-23 | dataset v1.1 | provider change observed | Phoenix pricing page showed Wegovy at both $399.99 (card) and $339.99 (table) | The $399.99 card was not found on that page; $339.99 remains. $399.99 still appears on Raven's homepage and in the linked Wegovy page's extracted text, so the conflict stays open as a cross-page one | R41-C39, R41-C40, R41-C42, R41-C43, R41-C47 | svc-phoenix-weight medication; conf-phoenix-wegovy-price | build chat | owner review pending | 2026-09-30 |
| 2026-09-23 | dataset v1.1 | provider change observed | Hims: English page free first weight consult, French page $99 | Both settled browser views show a free first consult; extracted text of both still shows $99. Conflict stays open. Free delivery and a local-pharmacy option now recorded | R41-C55, R41-C56, R41-C62, R41-C63 | svc-hims-weight; conf-hims-first-consult | build chat | owner review pending | 2026-09-30 |
| 2026-09-23 | site build 0.7 | addition | The methodology promised that overdue records show 'needs recheck'; the site displayed intervals only | Each availability record carries a recheck due date. The province filter checks it against today in the reader's browser and moves an overdue 'offered' record out of the matches with a 'needs recheck' label. Provider pages show the next due date | Implements the recheck promise in the methodology | /compare/ filter; /providers/ pages | build chat | owner review pending | not applicable |
| 2026-09-23 | site build 0.7 | correction | Evidence pages said both pharmacists read each page 'against the published paper' | Each page now says what it was read against, from its own recorded source: the full paper (41 published pages) or the abstract and extracted data (61) | The previous wording overstated the review for pages written from abstracts | 102 study explainers; /evidence/; /about/; /updates/ | build chat | owner review pending | not applicable |
| 2026-09-22 | site build 0.5 | correction | Held guideline pages were built into the public output with links from other pages; the answer index carried their passages; every explainer and hub closed with a fixed pending-review sentence left over from the writer template; About said all 105 explainers were read and that the site had no form | The three held pages are withheld from public output and unlinked; the answer index carries only pages cleared for publication; the closing sentence on every explainer is generated from the recorded review state; About says 102 explainers and 13 hubs were signed and three are held, and describes the contact forms; review bundles are no longer in the deploy folder | SEO and AI visibility audit of 22 September 2026 found the public output disagreeing with the review record and with itself | all evidence pages; /about/; /data/answers-index.json; robots.txt | build chat | owner review pending | not applicable |
| 2026-09-18 | dataset v3 | scope change | BC and Ontario first | All ten provinces and three territories from day one, with evidence depth tiers (full, moderate, programme-level only) and explicit unknown states; service availability table for seven services across 13 jurisdictions; Maple Yukon claim recorded as conflicting | Owner decision on national scope; national tables added by the research chat | coverage-by-jurisdiction; service-availability-by-jurisdiction | research chat (owner reviewed) | not yet reviewed by an independent reviewer | 2026-10-18 |
| 2026-09-18 | site build 0.1 | build | no site | Private prototype generated from the root data files: 27 pages, province and service filter, cost-component worksheet | Build chat, first private prototype for the reader test | all pages | build chat (Claude) | owner review pending | 2026-09-25 |
| 2026-09-18 | site build 0.2 | addition | one evidence page (semaglutide versus tirzepatide trials table) | Evidence library added: 105 study explainers and 13 topic hubs at /evidence/, plus a /medicines/ index. Every page carries its review state; none is published until a pharmacist signs it. Three pages are held back by the research chat. | Evidence library handoff from the research chat (R3-2 PubMed evidence base, 105 papers, 142 claim records) | all evidence pages; medicine pages now link to their hubs; navigation | build chat (Claude) | pharmacist review pending on every evidence page | 2026-12-18 |
| 2026-09-17 | dataset v2 | fact closure | indexed DPD statuses; four services; BC and Ontario coverage from indexed sources | 79 DPD records and six monographs opened; seven services; BC, Ontario, NB, NL and six other provinces from opened formulary documents; CPSO register matches for three named physicians | Round 2 prompts R2-1, R2-2 and R2-5 | products; services; coverage; conflicts | research chat (Codex and Claude runs, owner reviewed) | review-round2-2026-09-18 with five live spot checks | 2026-10-17 |
| 2026-09-16 | dataset v1 | initial | none | Round 1 research: 207 evidence rows, four-service comparison, ten-province coverage matrix | Initial research pass (modules A to F) | all | research chat (Codex run, owner reviewed) | three independent read-only reviews | 2026-10-16 |
Evidence library: last verified by page
Every page in the evidence library carries its own last-verified date and its review state. A page is published only once a licensed pharmacist has read it against its recorded source (full paper, abstract or publication record, as the page states) and signed it. Pages marked held stay unpublished even after review until their source document has been read directly and the page rewritten.
This table scrolls sideways.
Last verification by jurisdiction
The coverage record shows a document date and an access date for every province and territory on the coverage page and on each jurisdiction page. Service records show the access date and the recheck assumption on the compare page and on each provider record.
How to read a version
Dataset versions count research merges. Site build versions count generated pages. A new dataset version regenerates all affected pages; a build with no dataset change does not alter any fact.